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A novel Pfs38 protein complex on the 
surface of Plasmodium falciparum blood-stage 
merozoites
Gourab Paul1, Arunaditya Deshmukh1, Inderjeet Kaur1, Sumit Rathore5, Surbhi Dabral1, Ashutosh Panda6, 
Susheel Kumar Singh2,3,4, Asif Mohmmed1, Michael Theisen2,3,4 and Pawan Malhotra1*
Abstract 
Background: The Plasmodium genome encodes for a number of 6-Cys proteins that contain a module of six cysteine 
residues forming three intramolecular disulphide bonds. These proteins have been well characterized at transmission 
as well as hepatic stages of the parasite life cycle. In the present study, a large complex of 6-Cys proteins: Pfs41, Pfs38 
and Pfs12 and three other merozoite surface proteins: Glutamate-rich protein (GLURP), SERA5 and MSP-1 were identi-
fied on the Plasmodium falciparum merozoite surface.
Methods: Recombinant 6-cys proteins i.e. Pfs38, Pfs12, Pfs41 as well as PfMSP-165 were expressed and purified using 
Escherichia coli expression system and antibodies were raised against each of these proteins. These antibodies were 
used to immunoprecipitate the native proteins and their associated partners from parasite lysate. ELISA, Far western, 
surface plasmon resonance and glycerol density gradient fractionation were carried out to confirm the respective 
interactions. Furthermore, erythrocyte binding assay with 6-cys proteins were undertaken to find out their possible 
role in host-parasite infection and seropositivity was assessed using Indian and Liberian sera.
Results: Immunoprecipitation of parasite-derived polypeptides, followed by LC–MS/MS analysis, identified a large 
Pfs38 complex comprising of 6-cys proteins: Pfs41, Pfs38, Pfs12 and other merozoite surface proteins: GLURP, SERA5 
and MSP-1. The existence of such a complex was further corroborated by several protein–protein interaction tools, co-
localization and co-sedimentation analysis. Pfs38 protein of Pfs38 complex binds to host red blood cells (RBCs) directly 
via glycophorin A as a receptor. Seroprevalence analysis showed that of the six antigens, prevalence varied from 40 to 
99%, being generally highest for MSP-165 and GLURP proteins.
Conclusions: Together the data show the presence of a large Pfs38 protein-associated complex on the parasite 
surface which is involved in RBC binding. These results highlight the complex molecular interactions among the P. 
falciparum merozoite surface proteins and advocate the development of a multi-sub-unit malaria vaccine based on 
some of these protein complexes on merozoite surface.
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Background
Malaria is a worldwide health problem, with 250 mil-
lion people at risk and an estimated 438,000 deaths each 
year [1]. Despite introduction of effective drugs and 
vector control tools, elimination or even eradication of 
malaria remains a distant prospect. Development of an 
efficacious vaccine would be an important tool to com-
bat malaria. Since morbidity and mortality is associated 
with asexual parasite forms [2], blood-stage antigens 
have been major targets for vaccine development efforts. 
Unfortunately, all attempts to develop a malaria vaccine 
based on surface proteins from the Plasmodium falcipa-
rum merozoite have so far failed [3–6] possibly due to 
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insufficient understanding of the molecular architecture 
of the merozoite surface proteins and their organization 
on the merozoite surface.
Protein complexes are critical for host-pathogen 
interactions and for many of the biological processes 
involved in intercellular contacts [7]. Two merozoite 
surface protein complexes have a well-documented role 
in the invasion of erythrocytes. These are the P. falcipa-
rum merozoite surface protein-1 complex and the api-
cal membrane antigen 1/rhoptry neck (RON)-complex 
[8–13]. A family of proteins referred to as 6-Cys domain 
proteins have recently gained interest as vaccine candi-
date antigens because of their critical role for parasite 
growth in the infected hepatocyte and in the mosquito 
midgut [14, 15]. Ten members of the 6-Cys family have 
been described in Plasmodium species that infect pri-
mates, rodents or birds [16, 17]. These proteins contain 
modules of six conserved cysteine residues forming three 
intramolecular disulfide bonds between C1–C2, C3–C6 
and C4–C5. The numbers of 6-Cys modules vary from 
two to seven while the length of interspersed sequences 
between these modules varies from 7 to 160 aa [16, 18, 
19]. The repeat units found in these proteins show dou-
ble domain characteristics and are termed A-and B-type 
domains [18]. Several of the 6-Cys proteins are attached 
to the outer leaflet of the plasma membrane by GPI 
anchors, while a few are associated with the parasite sur-
face through protein–protein interactions [17, 20].
Pbs36 and Pbs36p, the two members of 6-Cys protein 
family are located on the surface of Plasmodium berghei 
sporozoites [14] and knock-outs of the correspond-
ing genes resulted in cessation of parasite development 
in infected hepatocytes [14, 21]. Accordingly, P. berghei 
Pbs36 and Pbs36p knock-out sporozoites failed to pro-
gress to the asexual blood stage in infected mice. Since, 
these mice were protected from a subsequent challenge 
infection with wild-type P. berghei, some have advo-
cated that Pfs36 and Pfs36p knock-out parasites may be 
developed for an attenuated vaccine [21–23]. The two 
sexual-stage 6-Cys proteins, Pfs230 and Pfs48/45, are 
well-established candidates for a transmission block-
ing vaccine because of their critical role in parasite fer-
tilization and growth in the mosquito midgut [24–28]. 
In comparison to the 6-Cys proteins of the hepatic and 
transmission stages, little is known about the 6-Cys pro-
teins expressed during the asexual blood stages. Four 
members of P. falciparum 6-Cys family, Pfs92, Pfs41, 
Pfs38 and Pfs12, are expressed at the asexual blood 
stages. Among these proteins Pfs41 and Pfs12 form a het-
erodimer on the merozoite surface and Pfs92 interacts 
with factor H that is recruited by merozoites to evade the 
human complement system [20, 29, 30].
Here, the association of Pfs38, Pfs41 and Pfs12 with 
each other and with other merozoite surface proteins was 
investigated using biochemical and several protein–pro-
tein interaction tools. The existence of a Pfs38 protein 
complex on merozoite surface and its interaction with 
human red blood cells (RBCs) were also explored. The 
analysis of the seroreactivity of members of the Pfs38 
merozoite surface complex show that these proteins are 
strongly recognized by naturally acquired antibodies 
from geographically distant areas, suggesting a functional 
role for this complex during the natural infection.
Methods
In vitro Plasmodium falciparum culture
Plasmodium falciparum strain 3D7 was cultured on 
human erythrocytes (4% haematocrit) in RPMI 1640 
media (Invitrogen) supplemented with 10% O+human 
serum using standard protocol described by Trager and 
Jensen [31]. Parasite cultures were synchronized by two 
consecutive sorbitol treatments 4  h apart following the 
protocol described by Lambros and Vanderberg [32].
Cloning of Pfs38, Pfs12 and Pfs41 and PfMSP‑165, GLURP 
(R2, R1, R0), SERA5
Pfs38 gene encompassing aa 22–328 was codon opti-
mized and synthesized from Genescript  Inc, USA. The 
6-Cys domain of Pfs38 (aa 153–328) was PCR amplified 
from the synthetic gene using the primer pair: forward 5′ 
GCCCATGGGATCCAAAAAGGTGCTGCGTATTCA-
CATCTCTAACGG 3′ and reverse 5′ GCGTCGACCTC-
GAGAATTTCTTCGCGTTC 3′ and cloned in pGEMT 
vector (Promega  corporation, USA). The fragment was 
sub-cloned in the pET 28b expression vector between NcoI 
and XhoI sites. Pfs41 gene encompassing aa 28–378 and 
Pfs12 gene encompassing aa 26–323 was codon-opti-
mized and synthesized from Genescript Inc, USA and sub-
sequently sub-cloned between NcoI/XhoI site of pET28b.
PfMSP-165 encompassing aa 1052–1664 was amplified 
by PCR from P. falciparum 3D7 cDNA using primer pair 
forward.
5′ GCGCGGCCGCATCCATGGGACAGT TATCATTT 
GATTTATA TAATAAA 3′ and reverse 5′ GCGTCGA 
CCTCGAGTGCATCACATCCACCATTATTTTC 3′ and 
cloned in pGEMT vector (Promega corporation, USA). The 
fragment was sub-cloned in the pET 28b expression vector 
between NcoI and XhoI site. GLURP (R2, R1, R0 fragments) 
and SERA5 was cloned as described earlier [33, 34].
Expression and purification of recombinant proteins
The pET28b plasmids having Pfs38 and PfMsp-165 genes 
were transformed in BL21 cells, while plasmids having 
Pfs12 and Pfs41 fragments were transformed in Rosetta 
Page 3 of 15Paul et al. Malar J  (2017) 16:79 
cells. Each culture was induced at 1  mM IPTG for 5  h 
at 37  °C. The cells were disrupted by sonication in Tris-
buffer (0.05  M Tris pH 8.0 and 0.15  M NaCl) with 9-s 
pulses at 9-s intervals for ten times using mini probe. The 
soluble and insoluble fractions were separated by cen-
trifugation and analysed by SDS-PAGE. The expressed 
proteins Pfs38, Pfs12 and Pfs41were found to be pre-
sent in inclusion bodies, while PfMSP-165 was found to 
be expressed as soluble protein. To purify the recombi-
nant proteins, each Escherichia coli culture was induced 
with 1 mM IPTG for 5 h at 37 °C. The cell pellet was sus-
pended in 1/20 volume of lysis buffer (0.05  M Tris, pH 
8.0, 0.15  M NaCl, 0.01  M DTT, 100  µg/mL lysozyme, 
1  mM PMSF, 1% Triton X-100). For Pfs38, Pfs41 and 
Pfs12 purification, the cell suspension was sonicated 
and centrifuged at 12,000×g for 30  min at 4  °C. Pellets 
were washed four times with Tris-buffer without Triton 
X-100. The inclusion bodies thus obtained were resus-
pended in 8  M urea. The suspension was incubated for 
30 min at room temperature and centrifuged at 12,000×g 
for 30  min at 4  °C. Supernatant containing solubilized 
protein was kept for binding with Ni+2-NTA+ resin for 
1 h at 4 °C with constant shaking. After binding, suspen-
sion was packed in a purification column and the resin 
was washed four times with 8 M urea buffer containing 
10  mM imidazole. Bound protein(s) was eluted in lysis 
buffer containing 8 M urea with different concentrations 
of imidazole. Eluted protein fractions were analysed on 
10% SDS-PAGE. Fractions containing almost pure pro-
tein were pooled and refolded by gently diluting the pro-
tein 40-fold in refolding buffer (0.05  M Tris pH-8, 1  M 
Urea, 1  mM EDTA, 0.5  M arginine, 0.4  mM triton X, 
1 mM reduced glutathione, 0.5 mM oxidized glutathione) 
with constant stirring at 4 °C for 24 h. The refolded pro-
teins were concentrated and dialyzed against 0.05 M Tris 
pH-8, 0.15 M NaCl and stored at −80 °C.
For the purification of PfMSP-165, the cell suspension 
was sonicated and centrifuged at 12,000×g for 30 min at 
4 °C and the supernatant was incubated with Ni+2-NTA+ 
resin for 1 h at 4 °C. After binding, suspension was packed 
in a purification column and the resin  was washed four 
times with non-denaturing buffer, 0.05 M Tris pH-8, 0.3 M 
NaCl containing 10 mM imidazole. Bound protein(s) was 
eluted in 0.05 M Tris pH-8, 0.15 M NaCl buffer contain-
ing different concentrations of imidazole. Eluted protein 
fractions were analysed on 10% SDS-PAGE. Fractions 
containing almost pure proteins were pooled and dialyzed 
against 0.05  M Tris pH-8, 0.15  M NaCl. The expressed 
proteins were run in reduced and non-reduced conditions 
and confirmed by Western blot analysis with monoclonal 
Anti-His antibody (Sigma Aldrich, USA). GLURP (R2, R1, 
R0 fragments) and SERA5 were expressed and purified as 
described earlier [33, 34].
Generation of antibodies against Pfs38, Pfs12 and Pfs41, 
PfMSP‑165, GLURP (R0, R1 and R2 fragment) and SERA‑5
Antibodies against Pfs38, Pfs12 and Pfs41 and PfMSP-165 
were raised in both mice and rabbit. The animals were 
housed and handled in accordance with the institutional 
and national guidelines. The Institutional Animal Ethical 
Committee at ICGEB, New Delhi, India, approved the 
animal use protocol described in the studies. The ani-
mals were bred under the guidelines of the authorizing 
committee. For the antibody generation, 5–6 weeks old 
female BALB/c mice were immunized with 25 μg of each 
protein: rPfs38, rPfs12 and rPfs41 and rPfMSP-165 emul-
sified in Freund’s complete adjuvant on day 0, followed by 
three boosts of proteins emulsified with Freund’s incom-
plete adjuvant on days 14, 28 and 42. The animals were 
bled for serum collection on day 49. For rabbit immuni-
zation, New Zealand white female rabbits were immu-
nized with 200 μg of either of the following recombinant 
proteins: rPfs38, rPfs12 and rPfs41 and rPfMSP-165 emul-
sified in Freund’s complete adjuvant on day 0, followed 
by three boosts emulsified with Freund’s incomplete 
adjuvant on days 21, 42 and 63. The animals were bled 
for serum collection on day 70. Antibody titres in serum 
samples were quantified by enzyme-linked immunosorb-
ent assay (ELISA). Antibodies against GLURP (R2, R1 
and R0 fragments) and SERA5 were raised according to 
protocols described earlier [33, 34].
Immunoblot analysis of Plasmodium falciparum merozoites
Briefly, P. falciparum merozoites were harvested and 
lysed with SDS sample buffer and boiled at 98  °C for 
15 min. After removing insoluble material by centrifuga-
tion (15,000×g for 15 min), the parasite lysate was run on 
SDS-PAGE and transferred to nitrocellulose membrane. 
The membranes were probed with rabbit anti-Pfs38 
(1:1000) or anti-Pfs12 (1:1000) or anti-Pfs41(1:1000) anti-
sera followed by goat anti-rabbit HRP conjugated second-
ary antibody (1:3000). The membranes were developed 
with DAB/H2O2 solution (Sigma Aldrich, USA).
Immunoprecipitation
Parasites in late schizont stage (44–46 hpi) were collected 
by saponin lysis and washed several times to remove RBC 
contamination. Lysates for immunoprecipitation were 
prepared in IP lysis buffer (250 mM Tris, 150 mM NaCl, 
1 mMEDTA, 1% NP-40, 5% glycerol; pH 7.4). Protein-A 
Agarose were used to bind 20 µg of polyclonal anti-Pfs38 
antibody or anti-PfMSP-165 antibody or anti-Pfs 12 or 
anti-Pfs41 antibody while Protein-A Agarose incubated 
with 20 µg of pre-immune antibody served as a control. 
After 12  h of incubation at 4  °C, each antibody bound 
protein-A Agarose was washed with PBS and incu-
bated with parasite lysate (~1 mg per 10 μL of Agarose). 
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After 12 h of incubation, protein-A Agarose beads were 
washed with wash buffer and bound proteins were eluted 
from the beads using the elution Buffer (Tris–Glycine pH 
2.8). Proteins in the immunoprecipitated samples were 
digested by in-solution trypsin digestion method. Sam-
ples were brought to a final volume of 100 µL in 50 mM 
ammonium bicarbonate (Sigma) buffer to adjust the pH 
to 7.8, reduced with 10  mM DTT (final concentration) 
for 1  h at room temperature (RT) and alkylated with 
40  mM iodoacetamide (Sigma  Aldrich, USA) for 1  h at 
RT under dark conditions. Proteins were digested by the 
addition of Promega sequencing grade modified trypsin 
(V511A) at a ratio 1:50 (w/w) of trypsin:protein. For com-
plete digestion, samples were placed in a water bath at 
37  °C for 18  h. After digestion, extracted peptides were 
acidified to 0.1% formic acid and analysed by Orbitrap 
VelosPro mass spectrometer coupled with nano-LC 1000 
(Thermofisher Scientific Inc, USA).
ELISA
In vitro interaction between members of the Pfs38 com-
plex was examined by ELISA, as described previously 
with minor modifications [35]. Briefly, 96-well microti-
tre plates were coated overnight with 2  µg/mL of Pfs38 
at 4  °C. After blocking the wells with 5% skimmed milk 
in PBS, recombinant GLURP R0, GLURP R1, GLURP 
R2, PfMSP-165, PfMSP-119, Pfs41, Pfs12 and SERA5 
were added in increasing concentrations of 2, 5, 10, 
and 20 µg/ml and plates were incubated for 2 h. For the 
ELISA interaction of glycophorin A with Pfs38, 1 µg/mL 
of glycophorin A was coated in microtitre plates at 4  °C 
and after blocking, increasing concentrations of Pfs38 
or GLURP R2 or PfMLH (non-specific protein) were 
added and plates were incubated for 2 h. For the inhibi-
tion assay, 2 µg/mL of Pfs38 was coated at 4 °C and after 
blocking, anti-Pfs38 antibodies were added in increasing 
concentration of 0.25, 0.5, 1 and 2 mg/mL and incubated 
for 30 mins. This was followed by incubation with glyc-
ophorin A protein at 20 µg/mL for 2 h. Bound proteins 
were detected through polyclonal antibody raised against 
the respective proteins for 1 h. Horseradish peroxidase 
(HRP)-conjugated anti-mouse or anti-rabbit antibod-
ies (1:3000) were added in each well for 1 h and binding 
was quantified after adding the substrate of phenylen-
ediaminedihydrochloride (Sigma Aldrich, USA) by meas-
uring the resulting absorbance at 490  nm in an ELISA 
microplate reader. All the experiments were done in trip-
licate and mean ± SEM was calculated.
Far western
Far western assay was carried out according to the pro-
tocol described earlier [36]. Briefly 1–5  µg of recombi-
nant Pfs38, Pfs41, Pfs12, PfMSP-165, PfMSP-119, and a 
non-specific protein PfMLH were separated by SDS-
PAGE and transferred to a membrane. The proteins on 
the membranes were denatured and renatured. These 
membranes were blocked with 5% skimmed milk and 
incubated with 2 µg/mL of purified interacting bait pro-
teins, i.e., recombinant GLURP R2 or Pfs38 or SERA-5 in 
protein-binding buffer (100 mM NaCl, 20 mM Tris (pH 
7.6), 0.5  mM EDTA, 10% glycerol, and 1  mM DTT) for 
2 h at RT. Membranes were washed to remove the non-
specific interactions and were incubated with rabbit 
anti-GLURP R2 (1:1000) or rabbit anti-Pfs38 (1:1000) or 
mouse anti-SERA5 antisera (1:500) overnight at 4 °C fol-
lowed by incubation with goat anti rabbit IRDye 800CW 
(1:15,000) or goat anti mouse IRDye 800CW (1: 15,000) 
for 2 h at RT. Finally, the membranes were imaged with a 
LI-COR Odyssey FC instrument.
Surface plasmon resonance (SPR) analysis
SPR assays were performed on BIACORE 2000 instrument 
(GE Healthcare) at 37  °C, using HBS-EP buffer (general 
purpose buffer, degassed and ready to use 0.01 M HEPES 
pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v Surfactant 
P20; GE Healthcare  Lifesciences, USA). Recombinant 
GLURP R2 was immobilized up to 400 response units in a 
flow cell of CM5 sensor-chip (GE Healthcare Lifesciences, 
USA). For kinetic measurements, increasing concentra-
tions of recombinant Pfs38 were injected over immobilized 
GLURP R2 as well as the reference flow cell, at a flow rate 
of 20 μL/min. The surfaces were regenerated with a pulse 
of 10 mM Glycine at pH 1.5 at the end of each injection 
cycle. Duplicate injections of the same concentration in 
each experiment were superimposable, demonstrating no 
loss of activity after surface regeneration. Reference-sub-
tracted sensorgrams were analysed using the Biacore eval-
uation software 4.1.1 (GE Healthcare Lifescienes, USA). To 
determine the kinetic parameters of the interaction, bind-
ing responses in the steady-state region of the sensorgrams 
were plotted against analyte concentration and fitted to 
the standard 1:1 (Langmuir) bimolecular interaction with 
simultaneous fitting of ka and kd.
Glycerol density gradient centrifugation
Briefly, schizont-stage parasite were lysed in 0.5% Noni-
det P-40/Hepes-buffered saline (10 mM Hepes at pH 7.0, 
150 mM NaCl, 2 mM MgCl2, 10 mM KCl, 0.5 mM EDTA, 
and protease inhibitors). Lysate was cleared by centrifu-
gation and 500 μL of lysate was layered on top of a 9-mL 
5–45% step glycerol gradient. Gradients were centrifuged 
at 38,000 rpm for 18 h at 4 °C ina SW41 rotor (Beckman). 
Twenty fractions of 0.5 mL each were collected from each 
gradient and equal volumes of each fraction were mixed 
with loading dye. Protein samples were resolved by SDS/
PAGE and analysed by Western blotting using anti-Pfs38, 
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anti-Pfs12, anti-Pfs41, anti-GLURP R2, anti-PfMSP-165 
and anti-SERA5 antibody. In-solution trypsin digestion 
of fraction 5 followed by LC–MS/MS analysis was done 
to confirm the protein.
Indirect immunofluorescence assay (IFA)
Confocal laser scanning IFAs were performed with P. falci-
parum asexual blood stages. Cell fixation, antibody incuba-
tion and imaging were performed by standard techniques 
and microscopic examination was performed using a A1 
confocal microscope (Nikon Instruments Inc, USA). Images 
were analysed using Nikon NIS Elements v 4.0 software. 
Imaris image was created using the software IMARIS v 4.0.
Erythrocyte binding assay
Erythrocyte binding assays were carried out as described 
previously [37]. Neuraminidase treatment of RBC was 
carried out as described previously [37].
Invasion inhibition assay
Anti-Pfs38 IgG and pre-immune IgG were added to 
highly synchronized schizont-stage cultures (2% haema-
tocrit and 1% parasitaemia) at final concentration of 2, 5 
and 10 mg/mL. The cultures were incubated for 40 h for 
schizont rupture and merozoite invasion. Parasitaemia 
was counted by flow cytometry. Percentage inhibition 
was calculated relative to the pre-immune sera. Bars indi-
cate mean ± SEM of duplicate measurements.
Seroreactivity analysis
ELISA analysis was performed to determine the serore-
activity of the proteins of the Pfs38 complex using sera 
from naturally infected malaria patients as described 
earlier [38]. Sera from 28 P. falciparum malaria patients 
in India and 28 P. falciparum malaria patients in Liberia 
was used, while sera from 28 Danish volunteers was used 
as a negative control. For assessing the conformation of 
three refolded 6-cys proteins; i.e. Pfs38, Pfs12 and Pfs41 
as well as PfMsp-165 these proteins were denatured with 
8 M Urea and seroreactivity was tested using 28 Liberian 
sera samples.
Results
Expression and purification of recombinant Pfs41, Pfs38, 
Pfs12 and PfMSP‑165 proteins in Escherichia coli
Gene fragments encoding the 6-Cys proteins: Pfs38, 
Pfs41, Pfs12, and PfMSP-165 were cloned in expression 
vector pET28b and recombinant proteins were expressed 
in E. coli (Fig.  1a). Recombinant 6-Cys proteins were 
purified to homogeneity under denaturing conditions 
and refolded by dilution into a refolding buffer containing 
glutathione, while PfMSP-165 was produced in the same 
expression system under standard native conditions. 
The four recombinant proteins were purified to near 
homogeneity and were analysed in SDS PAGE as well 
as western blot using anti-His antibody (Fig.  1b). Pfs38, 
Pfs12 and Pfs41 showed a shift in migration pattern on 
SDS PAGE between reduced and non-reduced proteins 
while PfMSP-165 being expressed as a soluble protein 
shows no difference in migration pattern (see Additional 
file 1). Specific antibodies were raised against these puri-
fied recombinant proteins in rabbit and mice. As dem-
onstrated by western blot analysis of parasite-derived 
polypeptides, anti-Pfs38, anti-Pfs41 and anti-Pfs12 rec-
ognized bands of ~40, ~43 and ~35 sizes in the parasite 
lysates prepared from schizont stage (Fig. 1c). These anti-
bodies also stained the merozoites and schizont stages, 
thereby indicating the expression of these 6-Cys proteins 
at asexual blood stages of P. falciparum (see Additional 
file 2A, B).
Identification of Pfs38 protein complex at asexual blood 
stages
The possibility of a large Pfs38 protein complex was 
assessed by immunoprecipitation of parasite-derived pol-
ypeptides isolated from a highly synchronized culture of 
late schizonts with an anti-Pfs38 antibody. LC–MS/MS 
analysis of immunoprecipitated polypeptides identified 
Pfs38, GLURP, MSP-1, and SERA5, suggesting that these 
polypeptides exist in the form of a complex (Table 1). IgG 
purified from preimmune sera did not precipitate any of 
these proteins. To confirm the existence of such a com-
plex, the same parasite extract was immunoprecipitated 
with an anti-PfMSP-165 antibody followed by LC–MS/
MS analysis. This analysis identified Pfs38, Pfs41 and 
SERA5 as interacting partners for MSP-1 (Table 2). These 
results were further corroborated in independent experi-
ments where parasite extracts were immunoprecipitated 
with anti-Pfs12 and anti-Pfs41antibodies. These antibod-
ies immunoprecipitated Pfs12, Pfs41, MSP-1, and SERA5, 
respectively (see Additional files 3 and 4). The full list 
of proteins identified in LC–MS/MS analysis for immu-
noprecipation with anti-Pfs38, anti-Pfs12, anti-Pfs41, 
anti-PfMSP-165 and preimmune antibody is provided in 
Additional files 5, 6, 7, 8 and 9. Collectively, these results 
suggest that Pfs38 is a part of a large protein complex 
referred herewith as Pfs38 complex consisting of GLURP, 
MSP-1, SERA5, Pfs12, and Pfs41 proteins. 
Protein–protein interaction analysis of Pfs38 with other 
merozoite surface proteins
The direct interactions among the proteins of Pfs38 com-
plex was examined by a number of biochemical tools. Far 
western analysis that detects the interaction between a 
membrane-bound prey protein and soluble bait proteins 
[36] was performed. Recombinant Pfs38 served as a prey 
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protein while GLURP (R0, R1, R2), Pfs41, Pfs12, PfMSP-
165, PfMSP-119 proteins and PfMLH protein [39] served 
as a bait in the two hybrid interaction analysis. As shown 
in Fig.  2a, Pfs38 interacted with the GLURPR2, SERA5, 
PfMSP-165, Pfs12, and Pfs41 proteins, while no signifi-
cant interaction was seen between Pfs38 and PfMSP-119 
or PfMLH proteins. Interactions among the proteins 
of Pfs38 complex were further confirmed by an ELISA-
based binding assays in which recombinant Pfs38 was 
allowed to interact with different regions of GLURP (R0, 
R1, and R2), PfMSP-165, PfMSP-119, Pfs41, Pfs12, SERA5, 
and PfMLH. As shown in Fig.  2b, all protein–protein 
(a)
(b) (c)
Fig. 1 Expression of 6-Cys domain proteins: Pfs41, Pfs38, Pfs12 and PfMSP-165. a Schematic showing the organization of the above-mentioned Plas-
modium proteins. Arrows mark the regions that were expressed in Escherichia coli. b Coomassie stained SDS-PAGE and immunoblots showing the 
purified Pfs41, Pfs38, Pfs12 and PfMSP-165. Immunoblots were performed using mouse monoclonal anti-his antibody. c Recognition of native Pfs41, 
Pfs38 and Pfs12 proteins in parasite lysate from asexual blood stages using their respective antibodies generated against recombinant proteins
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interactions seen in far western analysis were observed 
in the ELISA-based binding assay. Interestingly, no inter-
action was observed between Pfs38 and PfMSP-119, sug-
gesting that Pfs38 binds to a MSP-1 region upstream of 
the 19  kDa C-terminal region (Fig.  2b). A surface plas-
mon resonance analysis was next performed to assess the 
physical properties of the interaction between Pfs38 and 
GLURPR2. Recombinant GLURPR2 was immobilized 
on a CM5 sensor chip and increasing concentrations of 
recombinant Pfs38 were injected over the chip. Pfs38 
bound to GLURPR2 in a dose-dependent manner with an 
equilibrium dissociation constant (Kd) of 2.6 ×  10−8  M 
Table 1 Identification of malarial proteins immunoprecipitated using anti-Pfs38 antibody by LC/MS–MS analysis
Accession No. Name of protein Score Sequence  
coverage (%)
Unique  
peptides
Sequences of peptides 
identified
PFE0395c Pfs38 110 29.80 12 RYPNEEVKEEDR
EEGNLYTSQFSVPPVVLTHR
HSFSNSEIFER
YPNEEVKEEDR
YPNEEVKEEDRFNLNR
KIPGcDFNADYK
PF10_0344 Glutamate rich protein (GLURP) 94 22.87 15 GQHEIVEVEEILPEDKNEK
GQHEIVEVEEILPEDDKNEK
KNEFSVVEEK
SVSEPAEHVEIVSEK
DGPVPSKPFEEIEK
ETPVVDGPK
VqHEIVEVEEILPEDK
PFI1475w Merozoite surface protein 1 (MSP-1) 14 4.36 7 EAEIAETENTLENTK
ALSYLEDYSLR
YYNGESSPLK
FPSSPPTTPPSPAK
PFB034c Serine repeat antigen 5 (SERA-5) 0.00 3.61 3 TSPGLcLSK
TNNAISFESNSGSLEK
SYAFNPENYEK
Table 2 Identification of malarial proteins immunoprecipitated using anti-PfMSP-165 antibody by LC/MS–MS analysis
Accession No. Name of protein Score Sequence  
coverage (%)
Unique 
peptides
Sequences of peptides identified
PFI1475w Merozoite surface protein 1 (MSP-1) 568 48 73 VPYPnGIVYPLPLTDIHNSLAADNDK
INEIKNPPPANSGNTPNTLLDK
TLSEVSIQTEDNYANLEK
KLEALEDAVLTGYSLFQK
LNSLNNPHNVLQNFSVFFNK
YFLDVLESDLMQFK
LLEVYNLTPEEENELK
INEIKNPPPAnSGNTPNTLLDK
EAEIAETENTLENTK
PFB0340c Serine repeat antigen 5 (SERA-5) 70 12 10 NYAIGSDIPEKcDTLASNcFLSGNFNIEK
ESNTALESAGTSNEVSER
NYAIGSDIPEKcDTLASncFLSGNFNIEK
cDTLASNcFLSGNFNIEK
LPSnGTTGEQGSSTGTVR
TNNAISFESNSGSLEK
KYIDTQDVNKK
EHNGTNLIESK
ETPFTNILIHAYK
LPSNGTTGEQGSSTGTVR
PFE0395c Pfs38 15 12 4 YNVVSIETVLK
HSFSNSEIFER
SIGVNKHSFSNSEIFER
MnMITQGDKYSIFSK
PFD0240c Pfs41 7 9 2 GGNVSEAQADEYLNK
SLNIPNDILNYDVYNSSNNR
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(B)
(C)
(a)
(a)
(b)
(b)
(c)
(c)
(d)
(d)
(e)
Page 9 of 15Paul et al. Malar J  (2017) 16:79 
(Fig.  2c). Together, these results confirmed the associa-
tion between Pfs38 and other merozoite surface proteins.
Co‑localization and co‑sedimentation analysis confirm 
an association of Pfs38 with other 6‑cys proteins, SERA5 
and PfMSP‑165 on the merozoite surface
To know the localization of proteins of Pfs38 complex on 
the surface of P. falciparum merozoites, co-localization 
studies for these proteins were performed on intact mer-
ozoites by immunofluorescence staining using their spe-
cific antibodies. Pfs38 partially co-localized with GLURP, 
Pfs41, Pfs12, and MSP-1, advocating the co-existence of 
proteins of 6-Cys protein complex on the merozoite sur-
face (Fig. 3a–d). These results were corroborated by co-
sedimentation analysis of parasite-derived polypeptides. 
Western blotting and LC–MS/MS analysis of the glycerol 
gradient fractions revealed the presence of Pfs38, Pfs41, 
Pfs12, GLURP, MSP-1, and SERA5 in a single fraction, 
suggesting that these proteins exist in a complex on the 
parasite (see Additional files 10, 11).
Pfs38 binds to human erythrocytes
The putative role of the Pfs38 complex in the invasion of 
P. falciparum merozoite into host RBC was also inves-
tigated. In  vitro erythrocyte binding assays were per-
formed with three recombinant 6-Cys proteins using 
intact human RBCs as described earlier [37]. Plasmo-
dium vivax erythrocyte binding antigen region 2 (PvRII) 
[40] and ClpQ [41] were used as positive and negative 
controls, respectively. Pfs38 efficiently bound to human 
erythrocytes and the binding was found to be neuramini-
dase resistant. In contrast, neither Pfs12 or Pfs41 showed 
appreciable binding to human erythrocytes (Fig.  4a, b). 
No erythrocyte binding activity has been reported for 
GLURP and SERA5 so far. An earlier study using a cross-
linking assay with synthetic peptides derived from Pfs38, 
Pfs41 and Pfs12 and RBC membrane proteins indicated 
that these proteins might be binding to members of gly-
cophorin family present on the RBC membrane [42]. 
Although the binding of Pfs38 to human RBC was neu-
raminidase resistant, an ELISA-based interaction was still 
carried out between Pfs38 and glycophorin A protein.
Recombinant Pfs38 showed a dose-dependent interac-
tion with glycophorin A (Fig. 4c), while GLURP R2 from 
the same complex and PfMLH (non-specific protein) 
did not show interaction to glycophorin A. These results 
are in line with a recent finding where MSP-1 amino 
terminus region (Msp-183) was found to bind with gly-
cophorin A of human RBC even in the presence of neu-
raminidase treatment [43]. Furthermore anti-Pfs38 
antibodies could inhibit the interaction between Pfs38 
and glycophorin A by up to 70% at 2 mg/mL (see Addi-
tional file  12). Together, these results show that Pfs38 
protein of the Pfs38 protein complex binds to human 
erythrocyte via glycophorin A. Based on the results of 
interactions studies among the proteins of Pfs38 protein 
complex and interaction of Pfs38 with RBC surface, a 
model is proposed for the organization of Pfs38 protein 
complex (Fig. 4d) showing that Pfs12 and Pfs38 proteins 
are anchored to merozoite membrane by GPI domains 
and Pfs41 interacts with these proteins to stabilize 
them. Pfs38 binds RBC surface via glycophorin A, while 
PfMSP-165, GLURP and SERA5 bind to the axis gener-
ated by Pfs41, Pfs12 and Pfs38.
Invasion inhibition assay (GIA)
The inhibitory potential of anti-Pfs38 antibodies on the 
invasion of Plasmodium merozoites into RBCs were eval-
uated. An invasion inhibition assay was performed on P. 
falciparum 3D7 using the purified anti-Pfs38 IgG at dif-
ferent concentrations. IgG purified from pre-immune 
sera served as a negative control. Anti-Pfs38 IgG showed 
an inhibition of approximately 30–40% at a concentration 
of 10 mg/mL (Fig. 4e).
Humoral immune responses to the proteins associated 
with Pfs38 protein complex
The immunogenicity of the members of Pfs38 complex 
were evaluated during natural infections using plasma 
from Africa and India by ELISA. MSP-165, GLURPR2, 
Pfs38, Pfs12, Pfs41, and SERA5 proteins were frequently 
recognized by sera from Liberia in Africa with seropos-
itivity rates of 100, 96, 89, 89, 96, and 89%, respectively 
(see Fig.  5; Additional file  13). Interestingly, these anti-
gens were also recognized by sera from India with sero-
positivity rates of 80, 60, 60, 42, 40, and 46%, respectively 
(see Fig.  5; Additional file  13). The lower seropositivity 
rates observed among Indian samples may be related to 
a lower transmission intensity in this area compared with 
that of Liberia. The seropositivity of three refolded 6-cys 
(See figure on previous page.) 
Fig. 2 Existence of a Pfs38 protein complex at Plasmodium asexual blood stages. A Far western analysis showing interactions of recombinant Pfs38 
with Pfs12 (b), Pfs41(b), GLURPR2 (a), PfMSP-165(c), and SERA5 (d). Plasmodium PfMLH and PfMSP-119 (e) did not show interaction with Pfs38. B ELISA 
binding analysis confirming the interactions of Pfs38 with Pfs12 (a), Pfs41 (a), GLURPR2 (b), PfMSP-165 (c), and SERA5 (d) proteins, while Plasmodium 
PfMLH and PfMSP-119 did not show binding to Pfs38. Error bars represent mean ± SEM of duplicate measurements. C SPR analysis showing an 
interaction between Pfs38 and GLURPR2
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proteins, i.e. Pfs38, Pfs12 and Pfs41 as well as PfMsp-
165, were significantly reduced when these proteins 
were denatured with 8 M urea, thereby confirming their 
proper folding (see Additional file 14).
Irrespective of the differential reactivity, the relative 
high seroprevalence rates in both areas indicate that the 
6-Cys proteins: Pfs38, Pfs12, Pfs41, and MSP-1 as well as 
SERA proteins used in the present study, are good immu-
nogen and these proteins have adopted their natural 
folds. Taken together, these results indicate that proteins 
of the Pfs38 complex are expressed during the natural 
infection in geographical distinct parasite populations.
Discussion
An effective blood-stage vaccine to prevent the preva-
lence of malaria or ameliorate the severity of disease 
is still a distant prospect because of major gaps in the 
knowledge of Plasmodium biology, especially in the 
understanding of molecular architecture of merozoite 
surface as well as the critical events involved in the inva-
sion of RBCs. Among the many antigens that coat mero-
zoite surface, 6-Cys proteins are of significant interest as 
they are expressed at multiple stages of P. falciparum life 
cycle and have a characteristic arrangement of cysteine 
residues [18, 29, 44–46]. Although 6-Cys domain proteins 
(a)
(b)
(c)
(d)
Fig. 3 Expression and co-localization of proteins of Pfs38 complex on Plasmodium merozoites. Co-localization studies were performed by immu-
nofluorescence assays. Merozoites were labelled with (a) mouse anti-Pfs38 and rabbit anti-GLURP or with (b) mouse anti-Pfs38 and rabbit anti-Pfs41 
antibodies or with (c) mouse anti-Pfs38 and rabbit anti-Pfs12 antibodies or with (d) mouse anti-Pfs38 and rabbit anti-PfsMSP165 antibodies. Partial 
co-localization was observed between Pfs38 and other proteins of 6-Cys complex with co-localization coefficient of 0.75, 0.61, 0.82, and 0.83 for 
a–d, respectively. Td represent bright field images
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(a)
(b) (c)
(d) (e)
Fig. 4 Pfs38 binds human erythrocytes via Glycophorin A and is required for invasion of red blood cells. a Recombinant Pfs38, Pfs12 and Pfs41 were 
incubated with uninfected human erythrocytes and bound proteins were eluted from the erythrocytes after centrifugation through oil. PvRII was 
used as a positive control for erythrocyte binding assay, while an internal protein ClpQ was used as a negative control for the assay; b Erythrocyte 
binding assay of recombinant Pfs38 with untreated (UN) and neuraminidase treated (NM) RBCs. c Glycophorin A is the erythrocyte receptor through 
which Pfs38 binds human erythrocytes. ELISA binding assay was performed to study the interaction between Glycophorin A and recombinant 
Pfs38. As a control, GLURPR2 and PfMLH protein were used. Error bars indicate mean ± SEM of duplicate measurements; d A model of Pfs38 protein 
complex based on protein–protein interactions and protein-erythrocyte interaction; e Invasion inhibition assay was performed on schizont stage 
using α-Pfs38 purified IgG at concentration of 2, 5 and 10 mg/mL and percent inhibition was calculated. Bars indicate mean ± SEM of duplicate 
measurements
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were identified more than 20 years ago, their functions at 
asexual blood stages are yet to be defined.
To get insights into the role of three 6-Cys proteins: 
Pfs41, Pfs38 and Pfs12, at asexual blood stages, par-
ticularly in the invasion process, these proteins were 
expressed and purified in E. coli expression systems and 
specific antibodies to these proteins were raised. These 
antibodies were specific as they recognized specific 
bands in asexual blood stages of P. falciparum lysates and 
stained the merozoite surface. It has been shown that 
Fig. 5 Naturally-acquired humoral IgG immune responses to proteins of Pfs38 complex. Human IgG antibodies against proteins of 6-Cys complex 
were detected by ELISA in sera from naturally infected patients from Liberia and India. Sera from Denmark were used as a negative control. The 
dotted line indicates positivity thresholds determined from the mean reactivities +2 SD of 28 sera samples from Danish non-immune volunteers. 
African and Indian sera with OD above the positive thresholds are considered seropositive for each of the antigen. Bars represent mean ± SEM for 
28 sera samples
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Pfs12 and Pfs41 exist as heterodimer on the P. falciparum 
merozoite surface [20]. To know whether these proteins 
are part of a large network, the P. falciparum schiz-
ont stage parasite lysate was immunoprecipitated using 
either anti-Pfs38 or anti-Pfs41 or anti-Pfs12 antibody 
and the immunoprecipitated samples were analysed by 
LC–MS/MS. A similar approach has been adopted by us 
and others to identify protein complexes in Plasmodium 
and other organisms [47]. These analyses provided evi-
dence for the association of three 6-cys proteins (Pfs38, 
Pfs12 and Pfs41) with other merozoite surface proteins: 
GLURP, PfMSP-1 and SERA-5 on the merozoite surface. 
Careful analysis of the peptides generated in MS/MS 
analysis showed that a region upstream of the PfMSP-
119 is associated with the complex. Overall, these results 
suggested the existence of a large Pfs38 protein complex 
comprising of GLURP, SERA5, PfMSP-1, Pfs41, and Pfs12 
proteins.
In vitro protein–protein interaction tools, such as 
ELISA based binding assays and Far western blot analy-
sis between the six proteins of Pfs38 protein complex and 
co-localization studies, provided additional evidence for 
the existence of such a complex. The interaction between 
Pfs38 and GLURPR2 was further quantified by surface 
plasmon resonance (SPR) analysis in the present study. 
Although a couple of previous studies have shown an 
interaction between Pfs12/Pvs12 and Pfs41/Pvs41 [20, 
40], other interactions between the components of Pfs38 
complex have never been reported. Among the merozo-
ite proteins identified in Pfs38 complex, Pfs12 and Pfs38 
anchors to the merozoite membrane via GPI motif simi-
lar to several other merozoite surface proteins, while 
Pfs41, SERA5 and GLURP lack GPI-anchoring motifs 
and they interact with Pfs12 and Pfs38 via non-covalent 
interactions [16]. Although MSP-1 has a GPI anchoring 
motif, nonetheless this protein undergoes processing and 
region(s) of MSP-1 that interacts with this complex are 
distant from PfMSP-119, a region anchored to the mero-
zoite membrane [48].
Gene knock-out studies have shown that neither Pfs12 
nor Pfs41 are essential for the malaria parasite growth 
or invasion and antibodies to these antigens do not sig-
nificantly block erythrocyte invasion in vitro [20]. These 
proteins also did not show binding to human erythrocyte 
in an in vitro assay [20]. As the structural and biochemi-
cal characteristics of 6-Cys proteins predict their role(s) 
in the process of recognition and adhesion of host cells 
[26, 29], the possibility of Pfs38, Pfs41 and Pfs12 interac-
tion with human RBCs was explored. As shown previ-
ously, Pfs41 and Pfs12 did not show binding to human 
erythrocytes, however, Pfs38 bound to RBCs via glyco-
phorin A and anti-Pfs38 antibodies showed a moderate 
invasion (~40%) inhibition activity. These results are 
in line with a previous study where anti-Pfs38 antibody 
generated against a plant-produced recombinant Pfs38 
showed inhibition of  ≥60% [49]. Although a moderate 
level of invasion inhibition was observed with anti-Pfs38 
antibody, it is possible that for greater protection anti-
bodies to other components of the complex may also be 
required. This is evident in an earlier report that showed 
better protection against a Plasmodium yoelii challenge 
in mice immunized with PfAMA-1-RON2 complex in 
comparison to the mice immunized with each antigen 
alone [50]. Together these studies advocate the devel-
opment of a sub-unit malaria vaccine based on the can-
didates that are present in complexes with one or more 
binding partners instead of the individual component.
To explore whether the recombinant proteins used 
in interaction analysis were properly folded with intact 
conformational epitopes and are targets for naturally 
acquired humoral immunity, these six antigens of Pfs38 
protein complex were screened against plasma from 28 
Liberian and 28 P. falciparum-infected Indian patients. 
All the six antigens: Pfs38, Pfs12, Pfs41, PfMSP-165, 
GLURPR2, and SERA5 showed at least a two-fold change 
in IgG reactivity between the naïve sera and P. falcipa-
rum-exposed plasma in two geographically distinct popu-
lations. However, antibody responses among six antigens 
varied. GLURP R2 and PfMSP-165 showed significantly 
high antibodies than members of the 6-Cys family. Simi-
lar high responses have been observed against GLURPR2 
in a number of previous studies [33, 51, 52]. Differences 
in the humoral responses against these antigens between 
the Liberian and Indian sera were observed. The differ-
ence in the reactivity observed between Indian and Libe-
rian sera may be because Liberia is a malaria-endemic 
region, while Indian isolates were from non-endemic 
areas. Interestingly denaturing four of these antigens by 
urea treatment significantly reduced their reactivity with 
Liberian sera thereby further confirming the folding of 
recombinant proteins used in the present study.
Conclusions
In summary, the existence of a large Pfs38 complex on 
P. falciparum merozoites consisting of three 6-Cys fam-
ily members: Pfs38, Pfs41 and Pfs12 that associate with 
GLURP, PfMSP-165 and SERA5 was revealed. Pfs38 pro-
tein of this large Pfs38 complex binds to RBC via gly-
cophorin A. Two proteins of this complex: GLURP and 
PfMSP-165 showed high seroreactivity to sera from P. fal-
ciparum-infected patients with a seroprevalence of >90% 
from two geographically distinct populations. Although 
broader epidemiological investigations and in vivo chal-
lenge studies are required, the results of the present study 
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point towards developing malaria sub-unit vaccines 
based on merozoite surface protein complexes.
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